Abstract: Patients with low-grade (clinically indolent) lymphomas are at risk to undergo transformation to high-grade (clinically aggressive) lymphoma, although transformation only occurs in a subset of patients. When transformation occurs it is a critical event that determines the course of disease and is associated with unfavorable patient outcomes. Accurate detection of transformation, predictive biomarkers, and identification of specific molecular pathways implicated in the pathobiology of transformation will facilitate personalized therapeutic approaches and underpin advances in clinical outcomes. In this article, we present an update of the clinical and pathologic diagnostic criteria for low-grade B-cell lymphoma transformation and discuss the molecular alterations involved in the pathogenesis of this biological phenomenon.
B
-cell non-Hodgkin lymphomas can be broadly divided into 2 categories: low grade (indolent) and high grade (aggressive). High-grade B-cell lymphomas are typically associated with a rapidly progressive clinical course necessitating treatment with cytotoxic therapies. 1,2 Lowgrade B-cell lymphomas, in contrast, are characterized by a much more indolent clinical course, often requiring no intervention or conservative therapy. In what has been long recognized as a manifestation of the multistep cancer progression model, a subset of low-grade B-cell lymphomas undergo transformation to high-grade lymphoma during the disease course, herein referred to as histologic transformation.
Transformation of a low-grade lymphoma is often associated with clinical manifestations. Transformation is commonly a precipitous event whereby the patient goes from having an indolent clinical course to having rapidly progressive symptoms within a short period of time. The change in symptoms is typically associated with other clinical signs of transformation such as acute exacerbation of lymphadenopathy and other laboratory and imaging findings.
Advances in imaging and image-guided biopsy techniques have had a significant impact on how and at what timepoint transformation is detected. Transformation is typically suspected when a patient with a low-grade B-cell lymphoma develops unexplained B-type symptoms, rapidly enlarging lymph nodes, hypercalcemia, and/or significant elevation in serum lactate dehydrogenase (LDH) levels. 3, 4 Imaging studies are very helpful in defining the presence of a mass or masses. 18-fluorodeoxyglucose-positron emission tomography ( 18 FDG-PET) is very helpful, because this method detects sites of disease with relatively increased metabolic activity and/or vascularization expressed quantitatively as standardized uptake value (SUV). In a patient with suspected transformation, the identification of any lesion (nodal or extranodal) with increased 18 FDG avidity by PET (SUV > 5.0) is an indication for biopsy and tissue evaluation. Conversely, the absence of lesions by 18 FDG-PET has a 97% negative predictive value in excluding transformation. 5 The positive predictive value of 18 FDG-PET for transformation is generally proportional to the SUV; an SUV > 10 is predictive of aggressive lymphoma with 80% confidence and an SUV > 13 with >90% confidence. [5] [6] [7] Importantly, the utility of 18 FDG-PET is not impacted by the type of transformation (see below). 7 Tissue biopsy sampling is generally regarded as the most definitive means of documenting transformation. Optimal sampling is typically achieved best through an excisional biopsy, which allows for ample sampling and mitigates sampling bias. However, core biopsy sampling, with or without fine-needle aspiration cytology, is a commonly used diagnostic procedure. Core biopsy sampling is usually performed under image guidance using ultrasound for superficial lesions and computed tomography for deep lesions. Sampling should be aimed at accessible lesions with the highest 18 FDG avidity. Fine-needle aspiration alone is generally not recommended to assess for transformation because of high false-negative rates. 3, 8 Histologic manifestations of transformation include an increased number of large cells, numerous mitotic figures, and a high proliferation rate as shown by Ki-67 expression. The most common histologic manifestation of transformation is the presence of confluent sheets of neoplastic large lymphoid cells with increased proliferation supporting the diagnosis of diffuse large B-cell lymphoma (DLBCL). Less commonly, transformation can histologically resemble lymphoblastic lymphoma/leukemia, Burkitt lymphoma, plasmablastic lymphoma (PBL), or classical Hodgkin lymphoma (CHL).
Although the clinical and pathologic facets of transformation are congruent in most cases, on occasion one or the other might be inconspicuous. The occurrence of such discrepancies is not surprising when one considers the inevitability of sampling limitations and the fact that transformation is a molecularly heterogenous process that can be modulated by therapies for the underlying low-grade lymphoma. Notable among such discrepancies is the identification of increased numbers of large cells, often with accompanying increased proliferative activity as assessed by Ki-67 expression, without definitive confluent growth. Conversely, increased numbers of large cells or a notable elevation of proliferation rate may be seen occasionally in a patient during surveillance without clinical or laboratory evidence indicative of transformation. In such instances, the weight of data from 18 FDG-PET imaging, laboratory results, and pathologic examination should be considered in deciding whether or not transformation has occurred.
Patients with transformed low-grade B-cell lymphoma are regarded as having a poor prognosis. The main frontline treatment strategy is chemoimmunotherapy with various regimens being used on the basis of the type of low-grade lymphoma and prognostic factors. For example, the OFAR (oxaliplatin, fludarabine, cytarabine, and rituximab) regimen is often used for patients with transformed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 9 Although allogeneic stem cell transplantation is the standard option for treating patients who undergo remission and is the only modality that offers the potential for a cure, many patients do not qualify due to an inadequate response to induction therapy. 10 In this review, we provide an overview of the pathogenetic mechanisms underpinning histologic transformation in B-cell lymphoma and present an update of diagnostic criteria and challenges involved in the clinical and pathologic assessment of transformation in patients with CLL/SLL, follicular lymphoma (FL), marginal zone lymphomas (MZLs), and lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia (LPL/WM). Although mantle cell lymphoma is a small B-cell lymphoma, most patients do not have an indolent clinical course, and therefore it is not within the scope of this review.
CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Histologic transformation of CLL/SLL into a more aggressive neoplasm occurs in 2% to 12% of patients. 11 The most frequent type of transformation is the development of DLBCL. This phenomenon is broadly referred to as Richter syndrome (RS), a term introduced by Lortholary et al 12 in 1964 in reference to a case report 13 by Maurice Richter in 1928. RS (or transformation) is occasionally applied loosely to other less common types of CLL/SLL transformation such as Hodgkin lymphoma (HL). In this manuscript, we use the term RS to refer specifically to the development of DLBCL in a patient with CLL/SLL.
Enlarged lymph nodes by physical examination or imaging studies are often the first clue of RS in a patient with CLL/SLL. Laboratory studies commonly associated with transformation include a substantial (> 1.5 times the upper limit of normal) elevation in serum LDH and serum beta-2 microglobulin (b2M) (> 2 mg/L) levels. Hypercalcemia, new-onset absolute lymphocytosis Z5Â 10 9 /L, and thrombocytopenia <100 Â 10 9 /L commonly accompany RS, but these findings are not by themselves reliable predictors of RS. 4, 9, [14] [15] [16] [17] [18] [19] [20] [21] [22] 
DLBCL Transformation
Up to 10.7% of CLL/SLL patients develop RS, with an annual incidence rate estimated to be 1%/y. 3, 17, 23, 24 (Table 1 ) The wide variation in RS incidence may be attributed to a variety of factors that include the heterogeneity of patient populations studied, duration of followup, and diagnostic criteria used to define transformation (clinical/imaging vs. biopsy proven). The development of RS has been found to occur 1.8 to 4.0 years from the time of original CLL/SLL diagnosis, arising before or subsequent to CLL/SLL therapy. 17 Among patients with newly diagnosed CLL/SLL, the annual rate of RS is 0.5%. 17 RS may arise in any demographic subset of CLL/ SLL patients, but is most common in men over 60 years of age (Table 2) .
Significant overlap exists between the morphologic and immunophenotypic features of DLBCL arising in RS (RS-DLBCL) and de novo DLBCL, although such similarities fade at the molecular level, implying that these entities represent distinct diseases. 15, 27 Most RS-DLBCL tumors have centroblastic morphology, and only a minority of cases exhibit immunoblastic features. Mitotic figures and apoptotic bodies are usually abundant, and a starry-sky pattern and coagulative tumor necrosis are common. 28 Typically, the neoplastic cells are positive for the pan-B-cell markers CD19, CD20, CD22, and PAX5 as well as monotypic surface immunoglobulin (sIg) expression. CD5 and/or CD23 expression is retained to a varying extent, but CD38, ZAP-70, and CD49d are usually positive. 4, 17 Approximately 80% of RS-DLBCL have a non-germinal center B-cell-like (non-GCB) immunophenotype, negative for CD10 and positive for IRF4/MUM1, whereas the remainder display a germinal center B-cell-like (GCB) phenotype, positive for CD10 and/or BCL6 ( Figure 3) . 25, 29 Other features commonly seen in RS-DLBCL include p53 overexpression and a high (> 70%) Ki-67 proliferation index. Epstein-Barr virus (EBV) transcripts may be detected by colorimetric in situ hybridization in some cases. 3, 17, 28 Some patients with a history of CLL/SLL undergo biopsy, and the specimen shows some features suggestive of transformation, but unequivocal criteria for DLBCL are not met. These patients often, but not always, have a more aggressive clinical course, and the term accelerated phase of CLL/SLL has been used in the literature over the years. In a study by Gine et al, 30 the authors proposed that 3 morphologic findings support the diagnosis of accelerated phase CLL/SLL: (1) expanded proliferation centers (broader than a Â 20 microscopic field); (2) increased mitotic activity (> 2.4 mitotic figures/proliferation center); and/or (3) increased proliferation index within proliferation centers as indicated by high Ki-67 labeling (> 40%).
About 70% to 80% of RS-DLBCLs are clonally related to the underlying CLL/SLL and can have unmutated or mutated immunoglobulin heavy chain variable region (IGVH) sequences. 29 Commonly, RS-DLBCL arises from a dominant CLL/SLL clone after having acquired additional somatic mutations. 27 Factors associated with transformation in CLL/SLL are summarized in Table 3 and Figure 1 . Heritable germline polymorphisms in the CD38 31 and LRP4 32 genes have been reported to impart a higher risk for transformation, although the functional mechanisms underlying these associations remain to be determined.
The molecular characteristics of the B-cell receptor (BCR) have been suggested to have an impact on the risk for transformation. CLL/SLL patients with unmutated IGHV genes are at an increased risk for RS compared with those with mutated IGHV. 17, 20 A fraction of CLL/ SLL cases share common IGVH complementary determining region 3 motifs (stereotyped BCR) as a result of nonrandom recombination predispositions involving the V-D-J regions. Stereotypy implies the presence of a common antigenic stimulus. On the basis of stereotyped BCR, CLL/SLL can be segregated into various subsets. In one study, subset 8 using the IGHV4-39/IGHD6-13/ IGHJ5 was associated with the highest risk for RS, and stereotyped BCR as well as IGHV4-39 were independent predictors of RS risk. 33 In addition, the 5-year risk of developing RS seems to be higher in CLL/SLL with shorter (< 5000 bp) telomere length (18.9% vs. 6.4%). 25 Cytogenetic abnormalities such as del(11q22.3), del(17p13), del(15q21.3), del(9p21), and/or add(2p25.3) also have been associated with RS. 17, 27 The molecular profile of RS-DLBCL is complex. Two major transformation models have been suggested that lead to the development of RS from CLL/SLL. 27 Most RS cases follow a "linear" model of transformation by which the transformed lymphoma is a direct progeny of the "parent" CLL clone, whereas in a minority of cases a "branched" model of evolution is implicated in which distinct genetic lesions direct a common precursor cell to give rise to the CLL and RS clones independently ( Fig. 2A) . Leukemic presentation of RS is associated with the latter model.
The most common chromosomal copy number alteration (CNA) linked to the development of RS is loss of 17p (B40%) resulting in inactivation of TP53, which in turn results in significantly higher number of genetic lesions, including additional somatic mutations and chromosomal rearrangements, across the genome. Biallelic loss of 19p21/CDKN2A/B is also frequently seen in RS (B30%) and is associated with the "branched" model of evolution. 15 Of note, disruptions of TP53 and CDKN2A often coexist with MYC-activating events. Other recurrent chromosomal CNAs implicated in the pathogenesis of RS include +12, À 7q31.31-36.6, À 8p, and À 14q23.2-q32.33 as well as high-level amplifications of chromosomes 8, 11, 13, and 18. Absence of del (13q14) has also been associated with an increased risk for transformation to RS.
Several genes involved in a host of cellular and biological programs have been identified to be recurrently mutated in RS [34] [35] [36] [37] [38] [39] [40] ; however, genes involved in proliferation, apoptosis, and cell cycle regulation seem to specifically stand out. The most commonly mutated genes seemingly involved in the pathogenesis of RS include TP53 (tumor suppressor), NOTCH1 and MYC (proliferation), and CDKN2A/B (cell cycle regulation), together accounting for up to 90% of RS cases. 27 Unlike TP53 and CDKN2A/B, NOTCH1 mutations and other lesions associated with MYC activation are mutually exclusive. 37 Notably, TP53 mutations and activating NOTCH1 mutations are less common in de novo DLBCL. Additional pathways involved in the emergence of RS include the MAPK, Wnt, NF-kB, and TGF-b pathways. Whereas de novo DLBCL and RS share a minor subset of genes as part of their genetic signatures, including MYCactivation (GCB-derived DLBCL) and MYD88 mutations and CDKN2A/B loss (activated B-cell-derived DLBCL), RS-DLBCL lacks other abnormalities common in de novo DLBCL, such as inactivation of CREBBP/EP300, b2M, PRDM1/BLIMP1, and TNFAIP3/A20, as well as BCL2 and BCL6 translocations. 27 Additional factors predictive of the development of RS remain largely unknown. Konoplev et al 26 demonstrated that CLL/SLL patients with increased serum thymidine kinase 1 (TK1), a key cellular enzyme in DNA synthesis, are at higher risk for developing RS. Increased serum TK1 is significantly associated with male sex, elevated serum b2M levels, unmutated IGVH status, ZAP-70 expression, and lack of del(13q14.3) by fluorescence in situ hybridization. Further, RS patients with a higher serum TK1 level tended to be at a higher risk of death. 26 These observations were further corroborated by Szantho et al 41 who showed that increased serum TK1 levels in CLL patients is associated with advanced Rai stage, CD38 and ZAP-70 expression, and higher levels of absolute lymphocytosis.
Various chemotherapy regimens have been used in the treatment of patients with RS, and response to therapy is a good predictor of survival. The initial treatment approach for RS is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with an overall response rate of 67%. 3 
PBL Transformation
PBL is an aggressive B-cell malignancy, thought to be related to DLBCL, in which neoplastic cells exhibit morphologic and immunophenotypic features of plasma cell differentiation. 42 A few cases of plasmablastic transformation arising in patients with CLL/SLL have been reported. Patients range in age from 52 to 77 years, and most are men. 16, 18, 43 A serum or urine paraprotein can be detected, occasionally despite a normal serum immunoglobulin level. 16 In addition to typical plasmablastic features, residual CLL/SLL cells may be identified in some areas. The plasmablastic cells often express CD38, ZAP-70, CD138, BLIMP1, IRF4/MUM1, and XBP1, whereas CD5, CD20, PAX5, and IRF8 are commonly 61 Chigrinova et al 15 58 Parikh et al 17 CD38+* 93 Fan et al 4 57 Parikh et al 17 46 Chigrinova 25 Parikh et al 17 40 Fabbri et al 27 TP53w disruptionz 60 (12/20) Chigrinova et al 15 47 Rossi and Gaidano 25 36 Fabbri et al 27 21 Parikh et al 17 
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negative. Molecular studies demonstrate monoclonal IGHV gene 16 and MYC rearrangement. 43 The few patients with plasmablastic transformation reported in the literature died within 3 to 6 months after transformation. 16, 18, 43 
HL Transformation
Less than 1% of patients with CLL/SLL develop HL. 21, 44, 45 In a meta-analysis by Bockorny et al, 46 patients had a median age of 65.7 years at transformation (range, 34 to 88 y), and most were men. The median interval between CLL/SLL diagnosis and Hodgkin transformation is 4 to 6 years (Table 4) . Of note, patients with CLL/SLL who are treated with purine nucleoside analogs (fludarabine, cladribine) and develop HL seem to have worse outcomes compared with other CLL/SLL patients with HL transformation. 46, 47 Hodgkin transformation is characterized by Hodgkin and Reed-Sternberg (HRS) cells in a polymorphous inflammatory background distinct from the CLL/SLL, although often in the same biopsy specimen. 14 The inflammatory background consists of T cells and histiocytes, with or without abundant eosinophils. Coagulative necrosis is a common finding. 28 Any of the histologic subtypes of HL can be seen, with mixed cellularity type being most common. 46 Another unusual pattern that raises the possibility of HL transformation is the occurrence of HRS cells scattered in a monomorphous background of CLL cells. In some patients, follow-up biopsy specimens show unequivocal CHL as described above, but in other patients there is no subsequent HL. These lesions have been referred to in the literature as CLL/SLL with HRS cells.
By immunohistochemistry (IHC), HRS cells express CD30, CD15, and PAX5, and these cells are commonly positive for EBV. 29 HRS cells may be positive for CD20, but usually with variable intensity in 20% to 30% of cases 46 (Table 4) . It has been postulated that exposure to immunosuppressive chemotherapy in patients with CLL may increase the risk for HL transformation. The presumed etiologic process is the marked and prolonged reduction of CD4-positive and CD8-positive T lymphocytes allowing the proliferation and accumulation of EBV-positive B cells, eventually resulting in a high-grade lymphoma. 46, 48 In most patients with CLL/SLL that transform to HL, the CLL/SLL cells have mutated IGHV. 29 In one study, about 80% had mutated IGVH genes. This observed frequency is much higher than that observed in RS with DLBCL or conventional CLL/SLL. 29 
FOLLICULAR LYMPHOMA
FL is a GCB neoplasm that is composed of a variable mixture of centrocytes and centroblasts. The number of centroblasts is captured in a cytologic grading system that correlates loosely with clinical aggressiveness. Low-grade FL (grades 1-2) includes tumors comprised mostly of centrocytes with fewer centroblasts, whereas high-grade FL (grade 3) is defined by the presence of an increased number of centroblasts. Patients with FL, particularly low-grade tumors, often have an indolent clinical course, typically with multiple relapses. A critical event in the natural history of FL is transformation or "progression" to a more aggressive neoplasm that usually resembles DLBCL. The frequency of FL transformation varies widely, ranging from 10% to 60%, due to differences in detection methods and definitions. 49 Other forms of histologic transformation occur much less often including aggressive tumors with features of Burkitt lymphoma, PBL, and B-lymphoblastic lymphoma/leukemia. 50 FL transformation is frequently seen in men in the fifth to sixth decades of life (Table 5) . Clinical characteristics associated with poor prognosis in FL are also associated with high transformation risk, and they include age, sex, elevated serum LDH, advanced-stage disease, high age-adjusted Follicular Lymphoma International Prognostic Index scores, and primary method of treatment. 49, [51] [52] [53] [54] In patients with a clinical suspicion of transformation, imaging studies, particularly PET scan, are helpful tools that help guide the selection of a biopsy site. 6, 55 
DLBCL Transformation
The risk for FL transformation to DLBCL is B20% at 8 years. 56 In one study, the median interval to DLBCL transformation was 2.75 years (range, 1.3 to 5 y), with a cumulative transformation rate of 13%, 15%, and 26% at 5, 10, and 14 years, respectively. 53 In another study, the overall transformation rate at 5 years was 10.7%, with an estimated rate of 2%/y over the first 5 years. 54 Conflicting data exist regarding the relative risk for transformation in patients who are observed (watch and wait) compared with those who receive chemotherapy and/or rituximab. 51, 53, 54 The 10-year trans-FIGURE 2. Patterns of clonal evolution in B-cell lymphoma transformation. In the linear model (A) of transformation, more common in RS among patients with CLL/SLL, DLBCL originates directly from the major CLL/SLL clone following the acquisition of additional genetic alterations. In this model, the DLBCL and CLL/SLL clones show similar IGHV mutation profiles. In the branched model (B), more common in FL, clones derive directly from a common precursor cell (CPC) by way of acquiring distinct genetic lesions. Note that both clones share a subset of alterations with the CPC and with each other in addition to harboring distinct genetic lesions. In both models, a minor subclone arising from the CPC and already equipped with transformation-specific gene signatures may be present at the time of diagnosis and may later declare itself as bona fide transformation.
formation risk in patients with low-stage FL who receive radiotherapy was 18.5%. 57 Histologic evidence of DLBCL transformation, characterized by sheets of large cells, occurs in about 25% to 35% of FL patients. (Fig. 4) Typically, the biopsy specimen shows sheets of centroblasts and less commonly immunoblasts. The follicular growth pattern is lost, although some residual follicular structures may be evident. À , and CD43 À . A high Ki-67 proliferation rate is common. CD21 demonstrates the absence of follicular dendritic cells in DLBCL. 49 Rarely, FL may transform into DLBCL with anaplastic morphologic features and acquisition of CD30. 56, 58 Analysis of the molecular mechanisms of FL transformation has shown that the genome of transformed FL (tFL) is substantially more complex compared with indolent FL as demonstrated by the presence of high-level chromosomal CNAs as well as markedly aberrant somatic IGHV hypermutation patterns. 50, [59] [60] [61] Whereas a linear clonal evolution model is more prevalent in CLL/SLL transformation to DLBCL, a divergent evolution model is more common in FL transformation whereby FL and tFL arise from a common mutated ancestor cell through independent acquisition of distinct genetic lesions 59, 61 (Fig. 2B) . Two programs are deregulated in the ancestral clone that gives rise to both FL and tFL: the first involves factors associated with epigenetic modifications (KMT2D, EZH2, CREBBP, and EP300), and the second involves factors associated with resistance to apoptosis (eg, BCL2). These lesions are shared by FL and tFL, and both of these pathways may be potentially GCBs. 59, 61, 63 In addition to these abnormalities, tFL exhibits recurrent alteration of genes involved in the control of cell cycle progression (CDKN2A/B and MYC) and DNA damage responses (alternative biallelic loss of TP53 and CDKN2A), suggesting that loss of genetic stability and deregulated proliferation are critical steps in tFL development. 61 Another important tFL-specific lesion is MYC gene deregulation through chromosomal translocation, copy number gains, and point mutations.
MYC abnormalities provide multiple survival advantages to neoplastic cells through robust promotion of cell growth, metabolism, and genetic instability. Mutation or deletion of b2M and CD58 also seem to contribute to the transformation process by permitting the neoplastic cells to evade immune surveillance. Mutations in EBF1 and regulators of NF-kB signaling pathway (MYD88 and TNFAIP3) also have been shown to be acquired at transformation. Lastly, multiple point mutations, small deletions, and duplications may be identified in the following genes: PIM1, PAX5, Rho/TTF, MYC, BCL7A, CIITA, and SOCS1. 59, 61, 63 Several signaling pathways are recurrently dysregulated in FL and/or tFL; however, their contribution to the pathogenesis of the disease is not well understood. These pathways involve TNFRSF14, STAT6, HIST1H1E, ARID1A, ARID1B, CARD11, and CD79B, positive and negative regulators of NF-kB (TNFAIP3 and TNIK), and FOXO1. 59, 61, 63 tFL shows genetic similarities to GCB-DLBCL including a high frequency of BCL2 rearrangements, REL amplifications, and mutations of EZH2, GNA13, and TNFRSF14. However, biallelic deletions of CDKN2A/B, STAT6 mutations, ARID1A mutations, FAS mutations and/or deletions, and aberrations of KMT2D are significantly more common in tFL compared with de novo DLBCL. Despite the similarities between tFL and de novo DLBCL, tFL exhibits distinct genetic alterations involving oncogenic and tumor-suppressor pathways in comparison with de novo DLBCL. 59, 61, 63 The outcome of patients with DLBCL arising from FL has improved in the era of R-CHOP therapy with a reported median overall survival (OS) of 50 months after transformation and a 5-year OS of B73%. 54 Survival after transformation is shorter in patients who undergo transformation within 18 months of diagnosis, and combination chemoimmunotherapy regimens such as R-CHOP administered at the time of transformation confer a better survival advantage compared with patients who had received R-CHOP before transformation. There is no evidence to suggest that addition of autologous stem-cell transplantation to R-CHOP significantly impacts OS; however, larger studies are needed to further validate this observation. 54 tFL cases associated with genomic alterations involving TNFAIP3 (6q loss), MYC (gain on chromosome 8), and CDKN2A (loss on chromosome 9) are associated with poorer survival. 63 
B-cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma (BCLU)
A small percentage of patients with FL undergo histologic transformation to an aggressive B-cell neoplasm morphologically reminiscent of Burkitt lymphoma and classified as BCLU. [64] [65] [66] [67] [68] This form of transformation has been reported more commonly in women in the fifth to seventh decades of life. A summary of cases reported in the literature is provided in Table 6 . The transformed component often involves extranodal sites and may present synchronously or metachronously with FL. 66, 69 Morphologically, these tumors exhibit a diffuse pattern of growth, and the neoplastic cells are composed of medium to large "transformed" cells with few admixed reactive T cells and no stromal reaction. A starry-sky pattern, frequent mitotic figures, and prominent apoptosis are often seen. 49, 70 The neoplastic cells express pan-Bcell antigens (CD19, CD20, CD22, and CD79a), PAX5, and sIg. Expression of sIg may be absent in a subset of cases. CD10, BCL2, BCL6, and IRF4/MUM1 expression is variable. The Ki-67 proliferation index is 50% to 100%. 64, 66, 69, 70 Monoclonal IG gene rearrangement can be demonstrated by polymerase chain reaction but may be undetectable because of somatic mutations of IGVH. MYC rearrangement is seen in approximately 35% to 50% of cases. In contrast to BL where MYC is juxtaposed to the IG loci, in BCLU arising from FL, MYC rearrangements often result in the juxtaposition with non-IG loci. Concurrent BCL2 and MYC translocations are seen in B15% of these cases, and in this instance the term "double-hit lymphoma" can be used. In these cases, BCL2 translocation is thought to precede MYC rearrangement in the process of lymphomagenesis, and the acquisition of an MYC translocation is considered a critical oncogenic event in the transformation of FL to high-grade B-cell lymphoma. 65 BCL6 translocation is less frequently observed and may accompany either MYC (double-hit lymphoma) or both MYC and BCL2 rearrangements (triple-hit lymphoma). Cytogenetic analysis of BCLU will usually show a complex karyotype in 70 The presence of BCL2/MYC translocation is associated with poor patient outcome. 71 
B-lymphoblastic Leukemia Transformation
A small subset of FL will transform into a highgrade tumor with blastoid morphology and immature immunophenotype (TdT + ), resembling B-lymphoblastic lymphoma/leukemia. [72] [73] [74] [75] [76] The term blastoid FL or blastoid unclassified B-cell lymphoma may be more appropriate for these neoplasms. 77 This phenomenon is more commonly reported in men in their fourth to seventh decade of life. This form of transformation can occur concurrently with FL or subsequently, up to 13 years after the initial FL diagnosis. [72] [73] [74] [75] [76] 78 MYC rearrangements are frequently (58% to 61%) seen and considered to be a key event in the transformation of FL into a highgrade lymphoma with blastoid features and are thought to be secondary to BCL2 alterations, which are seen in B93% of these cases. 70, 72, 73, 79 Morphologically, the transformed tumor exhibits a diffuse pattern of growth and is composed of mediumsized cells with immature, fine nuclear chromatin. Mitotic figures are readily identifiable. By IHC the transformed tumor cells show an immunophenotype similar to that of lymphoblastic lymphoma-they are positive for pan-Bcell markers including CD19, CD20 (variable), CD22, CD79a (variable), and PAX5. These cells are also positive for CD10, BCL2, BCL6, and TdT in most cases. 68 Upregulation of p53 expression may be demonstrated by IHC in B38% of these cases and correlates with TP53 mutations. 72 CD45 may be absent. Myeloid-associated antigens CD13 and CD33 may be expressed, and the presence of these does not exclude the diagnosis of B lymphoblastic leukemia/lymphoma. Proliferation index using Ki-67 is generally high (up to 90%), but lower rates (B30%) have been reported. 49, 78 The clinical outcome of patients with blastoid FL is poor, with a median survival of 4 months (range, 0.8 to 9 mo). There is no consensus therapeutic regimen for these patients. Most patients are currently treated with rituximab-based regimens including R-CHOP and R-hyperCVAD. The role of stem cell transplantation in these patients is currently unclear. 72 
Plasmablastic Transformation
Plasmablastic transformation of FL is highly unusual with only few cases reported in the literature. It is more commonly encountered in men in their seventh and eighth decades of life (median, 70 y) and may be detected simultaneously with FL or occurs subsequently up to 34 months after the initial diagnosis of FL. Other than the immunosuppression induced by chemotherapy for FL, these patients do not have underlying immunodeficiency. Transformation may occur in lymph nodes or extranodal tissues. 16 Morphologically, PBL arising from FL shows a diffuse pattern of growth and comprises transformed neoplastic cells with immunoblastic or centroblastic cytologic features. Plasmablastic differentiation is supported by IHC analysis; the FL component is positive for pan-B-cell antigens including CD20 and PAX5, and the PBL component lacks CD20 and PAX5 expression and is positive for CD138, PRDM1/Blimp1, and IRF4/MUM1. Monotypic cytoplasmic light chain expression (mostly l) may be demonstrated by IHC. Cytogenetic and fluorescence in situ hybridization studies show evidence of BCL2 rearrangement in a subset of cases, usually in concordance with the FL component. Rare cases may exhibit concurrent MYC rearrangements and, similar to cases with blastoid transformation, is considered to be a secondary event. 16, 60 Patients respond variably to CHOP and similar regimens. Rituximab is not recommended, as these tumors lack CD20 expression. 16 
HL Transformation
Transformation of FL to a tumor that resembles, more or less, HL is exceedingly rare and is characterized by an increased number of large cells with HRS-like features. 80, 81 Similar to other forms of FL transformation, this form of progression may be detected simultaneously or months after the initial diagnosis of FL.
The atypical large cells are invariably positive for PAX5 and most often positive for CD30, CD20, CD15, BCL6, CD45, BOB1, and OCT2 expression. Overexpression of p53 may be detected in the large neoplastic cells. EBV infection may be identified by in situ hybridization or detection of EBV latent membrane protein-1 (LMP1) in a subset of cases. 82 In the absence of the typical immunophenotype of CHL (CD30 + , CD15 + , CD45 À ), "Hodgkin-like" transformation is the preferred terminology.
A composite lymphoma in the setting of simultaneous presentation or a secondary clonally unrelated lymphoma in cases with metachronous presentation may be considered in the differential diagnosis of this phenomenon; however, strong expression of CD20, BOB-1, and OCT-2 in the "Hodgkin-like" cells in a patient with FL strongly argues for Hodgkin-like transformation of FL rather than de novo CHL. 80 The molecular alterations involved in the pathogenesis of transformation of FL to HL are unknown, and limited data exist on the outcome of these patients.
MARGINAL ZONE LYMPHOMA
Histologic transformation to a higher-grade B-cell lymphoma can occur in all types of MZL-splenic MZL (SMZL), nodal MZL, and extranodal MZL of mucosaassociated lymphoid tissue (MALT lymphoma). Transformation has been reported in 11% to 14% of patients, with a median time to transformation of 13 months after the initial diagnosis of MZL. 83, 84 The most common histologic form of transformation is DLBCL. [85] [86] [87] [88] [89] In addition, transformation of MZL to a more aggressive neoplasm may occur in the form of HL 90, 91 or Burkitt lymphoma. 92 Occasionally, SMZL may undergo prolymphocytoid transformation reminiscent of B-prolymphocytic leukemia. 93 In a study of 197 MZL cases by Meyer et al, 83 a high Follicular Lymphoma International Prognostic Index and a history of additional malignancies were the only factors found to be independent predictors of transformation by multivariate analysis. In addition, treatment with alkylating agents also conferred an increased risk for transformation. Among cases of transformed MZL in their study, 61% were MALT, 26% nodal marginal zone lymphoma, and 13% SMZL.
Clinical features commonly associated with histologic transformation of other types of low-grade lymphoma may be observed in patients with transformed MZL. Such features include B symptoms, poor performance status, disseminated disease, and elevated serum LDH levels. 87 The prognosis of patients with transformed MZL is poor and independently associated with shorter OS; the median OS is 8.4 months to 3.07 years after transformation (range, 0 to 8 y), and the 5-year OS rate is 33% for patients with transformed SMZL. 84, 87 
DLBCL Transformation
Transformation of MZL to DLBCL is characterized by the presence of sheets of large cells that often (but not always) represent >50% of all lymphoma cells. 87 Obviously, this criterion is conservative. There are cases of MZL with increased, often numerous large cells, but there is no cutoff for large cells and if sheet-like growth of large cells is absent the recognition of transformation is problematic. The rate of transformation of SMZL to a large Bcell lymphoma is reported to be 11% to 19%. 85, 87, 94 Large cell transformation can develop 3 to 192 months (median, 22.9 to 36.5 mo) after diagnosis/splenectomy in the case of SMZL. 85, 87, 94 Transformation to DLBCL may also occur among patients with MALT lymphoma. Approximately 12% of MALT lymphoma cases transform into an aggressive lymphoma. In the case of gastric MALT lymphoma, an association has been observed between lack of response to therapy for Helicobacter pylori infection and an increased risk for transformation to DLBCL. 95, 96 In rare instances, reactivation of latent EBV infection may lead to large cell transformation in MALT lymphoma. 97 The median age of patients with transformed MALT lymphoma is 58 years. Most patients present with disseminated disease at the time of transformation. The spleen and bone marrow are often involved. Peripheral blood involvement, elevated serum LDH and/or b2M levels, absolute lymphocytosis, thrombocytopenia, and presence of IgM paraprotein may be observed in a subset of patients. 85, 87, 94 Histologically, transformed centroblasts and/or immunoblasts are seen in variable numbers, occasionally with plasmacytic differentiation. Increased number of histiocytes, mitotic figures, apoptotic cells, and punctate or frank necrosis may be observed. The IHC profile of the transformed component is similar to that of the low-grade MZL. Occasionally, BCL6 and CD10 expression and p53 overexpression may be observed. The Ki-67 proliferation index is generally high (B40% to 80%). 85, 88 Rarely, EBV infection may be detected using in situ hybridization and has been postulated to be a causative agent for transformation. 94, 97 FOXP1 expression is seen in the transformed tumor cells of MZL, and its expression has been postulated to play a role in the process of transformation. 98 Cytogenetic studies have shown an increased frequency of del(7q) (B42%) in cases of transformed SMZL. 85, 94, 99 BCL6 gene rearrangements also have been shown to be associated with large cell transformation of extranodal MZL. 100 A high prevalence of TP53 alterations has been shown in cases of MZL with large cell transformation. 85, 94 Dysregulated expression of microRNAs involved in the MYC and NF-kB pathways has been shown to be associated with aggressive disease course in ocular adnexal MALT lymphoma. 101 NOTCH2 mutations in SMZL at the time of diagnosis have been shown to predict an unfavorable disease course as characterized by refractoriness to therapy, histologic transformation, and clinically aggressive disease. 102 The median OS after transformation is of 104 months, with a 5-year OS of 72% irrespective of MZL subtype. 83 An analysis of postsplenectomy SMZL patients revealed that after high-grade transformation, the median progression-free survival was 1.38 years, and median OS was 3.07 years. 87 
HL Transformation
Rarely, MALT lymphoma may be seen in association with HL. In a meta-analysis by Oka et al, 90 in most patients the MALT lymphoma and HL presented synchronously as a composite lymphoma; however, in a small subset of cases (B25%) patients developed HL 11 and 15 years after the diagnosis of MALT lymphoma. Histologically, HRS-like cells are present in a background of abundant inflammatory cells including eosinophils, plasma cells, and reactive lymphocytes. By IHC, HRS cells express CD30 and CD15. Weak CD20 and CD79a expression may be observed, and EBER is positive in a subset of cases. The clonal relationship between the MALT lymphoma and HL in the cases included in their study remains unclear. 90 A case of MZL with HL transformation seen at our institution is illustrated in Figure 5 .
LYMPHOPLASMACYTIC LYMPHOMA/ WALDENSTROM MACROGLOBULINEMIA
High-grade transformation occurs in approximately 1% to 19% of LPL/WM cases according to various studies. [103] [104] [105] [106] [107] [108] Almost all reported transformed cases were in patients who met criteria for WM. There are data that suggest that WM patients who are treated with nucleoside analogs exhibit an increased risk for large cell transformation. 103, 104, 106, 107, 109 The median time from treatment with nucleoside analog to transformation is B5 years (range, 0 to 14 y), and the 15-year probability of developing transformation is B21%. 104 There are limited data available on the outcome of patients with transformed WM.
DLBCL Transformation
Most patients with WM who transform develop DLBCL. [103] [104] [105] [106] [107] [108] [110] [111] [112] Occurrence of DLBCL can be simultaneous or sequential. The interval from the time of diagnosis to transformation ranges from 12 to 168 months (median, 44 to 72 mo). 104, 107, 110 Large cell transformation occurs more frequently in women with a median age of 56 years (range, 42 to 80 y). 110, 111 Lymphadenopathy, splenomegaly, anemia, leukopenia, thrombocytopenia, bone marrow infiltration, elevated serum LDH, and elevated serum monoclonal IgM may be seen in the setting of transformation. [110] [111] [112] Transformation may occur within the bone marrow or may involve extramedullary sites including lymph nodes or extranodal tissues 104 (Fig. 6) . DLBCL transformed from WM shows a diffuse and sheet-like proliferation of large neoplastic cells. 111, 112 The large cells are positive for pan-B-cell antigens including CD19, CD20, CD79a, and PAX5 and are negative for T-cell antigens. CD10 expression may be present. Immunophenotypic analysis using either IHC or flow cytometry may show monotypic immunoglobulin expression in cases with plasmacytic differentiation. Detection of identical light chain restriction in the WM and DLBCL components suggests a clonal relationship and transformation of WM rather than de novo DLBCL, but molecular studies are needed to be definitive. [110] [111] [112] There is no known association between MYD88 status and risk for transformation in patients with WM.
HL Transformation
Few case reports have described CHL transformation in patients with WM. 104, 110, 113 The time to transformation to HL is variable and may occur as early as 3 months and up to 16 years after the initial diagnosis of WM. HL transformation usually occurs in nodal sites and most often resembles the nodular sclerosis subtype of HL. The lacunar cells of HL are identified in a background of inflammatory 
Burkitt Lymphoma-like Transformation
Rarely, WM may transform into a high-grade lymphoma resembling Burkitt lymphoma. Morphologically, diffuse infiltration by a monomorphic population of predominantly medium-sized atypical lymphoid cells associated with a "starry sky" pattern is the diagnostic clue. The immunophenotype is similar to that of de novo Burkitt lymphoma (CD20 + , CD10 + , BCL2 À ), and the Ki-67 proliferation index is close to 100%. Polymerase chain reaction studies have demonstrated identical immunoglobulin gene rearrangement patterns in cases of WM and subsequent Burkitt-like lymphoma, confirming a common origin for these tumors in a subset of cases described previously in the literature. Transformation to Burkitt-like lymphoma has been shown to be associated with activation of MYC, loss of ETV6 at 12p13, and loss of TP53/chromosome 17p. 114 
CONCLUSIONS
A subset of patients with low-grade (clinically indolent) lymphoma transform to a clinically aggressive, high-grade lymphoma, and biomarkers that can aid in predicting the risk for transformation are needed. Histologic transformation, when it occurs, is a critical event that dictates the clinical course and outcome of these patients. Therapeutic management of patients with transformation of low-grade lymphoma continues to be challenging, as it remains difficult to construct standardized therapeutic regimens given the biological heterogeneity and lack of prospective randomized clinical trials. Early detection of transformation and identification of specific molecular pathways implicated in transformation will facilitate personalized therapeutic approaches and hopefully a better prognosis for these patients in the future.
